William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) , a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products.Eupraxia’s lead drug EP-104GI is currently in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis (EoE).Last week, Eupraxia shared symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial.Early Symptom Data Shows Dose-Dependent ImprovementThe tr ...